Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7, 2023Caroline SeymourNo difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hemato

Updated on: October 11,2023 258

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7, 2023Caroline SeymourNo difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hemato

Updated on:October 11,2023 258

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on: October 11,2023 205

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on:October 11,2023 205

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on: October 11,2023 56

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on:October 11,2023 56

Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

September 11, 2023Kyle DohertyThe addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival c

Updated on: October 11,2023 24

Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

September 11, 2023Kyle DohertyThe addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival c

Updated on:October 11,2023 24

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on: October 11,2023 222

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on:October 11,2023 222

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on: October 11,2023 261

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on:October 11,2023 261

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on: October 11,2023 261

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on:October 11,2023 261

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou

Updated on: October 11,2023 148

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou

Updated on:October 11,2023 148

Exploring the links between diet and cancer

Omer Yilmaz’s work on how diet influences intestinal stem cells could lead to new ways to treat or prevent gastrointestinal cancers.Anne Trafton|MIT News OfficePublication Date:May 25, 202

Updated on: October 11,2023 130

Exploring the links between diet and cancer

Omer Yilmaz’s work on how diet influences intestinal stem cells could lead to new ways to treat or prevent gastrointestinal cancers.Anne Trafton|MIT News OfficePublication Date:May 25, 202

Updated on:October 11,2023 130

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on: October 11,2023 66

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on:October 11,2023 66

Helping blood cells regenerate after radiation therapy

Method boosts differentiation of stem cells into mature blood cell types, may help leukemia and lymphoma patients.Anne Trafton|MIT News OfficePublication Date:October 24, 2018 PRESS INQUIR

Updated on: October 11,2023 239

Helping blood cells regenerate after radiation therapy

Method boosts differentiation of stem cells into mature blood cell types, may help leukemia and lymphoma patients.Anne Trafton|MIT News OfficePublication Date:October 24, 2018 PRESS INQUIR

Updated on:October 11,2023 239

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on: October 10,2023 265

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on:October 10,2023 265